Rufinamide is used to treat seizures caused by Lennox-Gastaut syndrome, it will be available as tablets in 200 mg and 400 mg strengths.

Glenmark Pharmaceuticals today said it has been granted tentative approval by the US health regulator to sell Rufinamide.